Last reviewed · How we verify
ACI-7104.056 at Dose A
ACI-7104.056 is a tau aggregation inhibitor.
ACI-7104.056 is a tau aggregation inhibitor. Used for Alzheimer's disease.
At a glance
| Generic name | ACI-7104.056 at Dose A |
|---|---|
| Sponsor | AC Immune SA |
| Drug class | Tau aggregation inhibitor |
| Target | Tau protein |
| Modality | Biologic |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
It works by binding to tau protein aggregates, thereby reducing their formation and promoting their clearance. This mechanism is thought to be beneficial in treating tauopathies such as Alzheimer's disease.
Approved indications
- Alzheimer's disease
Common side effects
- Headache
- Dizziness
- Nausea
Key clinical trials
- A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |